Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients

World Journal of Gastroenterology

Volumn 15, Issue 33, 2009, Pages 4177-4182

  He, Zi Li ^a   Zheng, He ^a   Lin, Hui ^a   Miao, Xiong Ying ^a   Zhong, De Wu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Polo like kinase 1; Reverse transcription polymerase chain reaction; Survival analysis

Indexed keywords

MESSENGER RNA; POLO LIKE KINASE 1; TUMOR MARKER; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER NODULE; LIVER RESECTION; MALE; PATHOLOGY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION; AGED; CHEMISTRY; GENETICS; LIVER TUMOR; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 70449730495     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4177     Document Type: Article

References (45)

1. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-5107 (Pubitemid 37059591)
2. Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 42-49
3. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790-800 (Pubitemid 44157567)
4. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007; 141: 196-202
5. Ueno Y, Moriyama M, Uchida T, Arakawa Y. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 2001; 33: 357-362 (Pubitemid 32120140)
6. Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, Sakano S, Furuya T, Oga A, Naito K, Sasaki K. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006; 70: 231-237 (Pubitemid 44154697)
7. Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000; 196: 753-759 (Pubitemid 30946900)
8. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006; 66: 5836-5846 (Pubitemid 43927138)
9. Spankuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 2008; 10: 223-234 (Pubitemid 351328583)
10. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 2007; 26: 5793-5807 (Pubitemid 47312808)
11. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148-152 (Pubitemid 36575873)
12. Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, Dietel M, Denkert C. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 2005; 11: 5644-5650 (Pubitemid 41684917)
13. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001; 169: 41-49 (Pubitemid 32532095)
14. Tang L, Wang TT, Wu YT, Zhou CY, Huang HF. High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis. Fertil Steril 2009; 91: 979-987
15. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15: 687-692
16. Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM, Zhang Y, Du XL, Luo ML, Xu X, Han YL, Cai Y, Zhang ZQ, Zhan QM, Wang MR. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 2009; 124: 578-588
17. Bu Y, Yang Z, Li Q, Song F. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology 2008; 74: 198-206
18. Chen XH, Lan B, Qu Y, Zhang XQ, Cai Q, Liu BY, Zhu ZG. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. World J Gastroenterol 2006; 12: 29-35 (Pubitemid 43126079)
19. Weichert W, Ullrich A, Schmidt M, Gekeler V, Noske A, Niesporek S, Buckendahl AC, Dietel M, Denkert C. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 2006; 97: 271-276
20. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, Ozaki M, Ito H, Ikeguchi M. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006; 70: 126-133 (Pubitemid 43760338)
21. Jang YJ, Kim YS, Kim WH. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol 2006; 29: 589-594
22. Dietzmann K, Kirches E, von Bossanyi, Jachau K, Mawrin C. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001; 53: 1-11 (Pubitemid 32936653)
23. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, Hiyama E, Hayashi Y, Ando H, Suita S, Kaneko M, Sasaki F, Hashizume K, Ohnuma N, Nakagawara A. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 2004; 23: 5901-5911
24. Wang XQ, Zhu YQ, Lui KS, Cai Q, Lu P, Poon RT. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma. Clin Cancer Res 2008; 14: 6813-6820
25. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 2794-2797 (Pubitemid 29283110)
26. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S. Expression of Polo-Like Kinase (PLK1) in non- Hodgkin's lymphomas. Leuk Lymphoma 2005; 46: 225-231 (Pubitemid 40185952)
27. Sun Q, Zhang Y, Liu F, Zhao X, Yang X. Identification of candidate biomarkers for hepatocellular carcinoma through pre-cancerous expression analysis in an HBx transgenic mouse. Cancer Biol Ther 2007; 6: 1532-1538 (Pubitemid 351590323)
28. Strebhardt K, Kneisel L, Linhart C, Bernd A, Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA 2000; 283: 479-480 (Pubitemid 30062860)
29. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29: 354-358 (Pubitemid 34888219)
30. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 543-549 (Pubitemid 27090956)
31. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M, Dietel M, Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90: 815-821 (Pubitemid 38406592)
32. Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004; 90: 414-418
33. Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 2004; 3: 641-646 (Pubitemid 39193743)
34. Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, Bahra M, Denkert C, Dietel M, Kristiansen G. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005; 5: 259-265 (Pubitemid 40754747)
35. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60: 240-245 (Pubitemid 38971835)
36. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007; 67: 10148-10158 (Pubitemid 350070786)
37. Zhou T, Aumais JP, Liu X, Yu-Lee LY, Erikson RL. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003; 5: 127-138 (Pubitemid 36827347)
38. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008; 320: 1655-1658 (Pubitemid 351931258)
39. Kang YH, Park JE, Yu LR, Soung NK, Yun SM, Bang JK, Seong YS, Yu H, Garfield S, Veenstra TD, Lee KS. Self-regulated Plk1 recruitment to kinetochores by the Plk1- PBIP1 interaction is critical for proper chromosome segregation. Mol Cell 2006; 24: 409-422 (Pubitemid 44754942)
40. Yuan JH, Feng Y, Fisher RH, Maloid S, Longo DL, Ferris DK. Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase. Mol Cancer Res 2004; 2: 417-426 (Pubitemid 39031075)
41. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002; 3: 341-348 (Pubitemid 34467604)
42. Jackman M, Lindon C, Nigg EA, Pines J. Active cyclin B1- Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003; 5: 143-148 (Pubitemid 36204196)
43. Li M, Zhang P. The function of APC/CCdh1 in cell cycle and beyond. Cell Div 2009; 4: 2
44. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397-405 (Pubitemid 27243915)
45. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000; 2: 672-676 (Pubitemid 30742844)